1
|
Shigeno T, Kozaka T, Kitamura Y, Ogawa K, Taki J, Kinuya S, Shiba K. In vitro and in vivo evaluation of [ 125/123I]-2-[4-(2-iodophenyl)piperidino]cyclopentanol([ 125/123I]-OI5V) as a potential sigma-1 receptor ligand for SPECT. Ann Nucl Med 2021; 35:167-175. [PMID: 33417152 DOI: 10.1007/s12149-020-01552-w] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 10/28/2020] [Indexed: 11/26/2022]
Abstract
INTRODUCTION We investigated the characteristics of radio-iodinated 2-[4-(2-iodophenyl)piperidino]cyclopentanol (OI5V) as a single photon emission computed tomography (SPECT) ligand for mapping sigma-1 receptor (σ-1R), which plays an important role in stress remission in many organs. METHODS OI5V was synthesized from o-bromobenzaldehyde in three steps. OI5V was evaluated for its affinity to VAChT, σ-1 and σ-2 receptor by in vitro competitive binding assays using rat tissues and radioligands, [3H]vesamicol, ( +)-[3H]pentazocine and [3H]DTG, respectively. [125/123I]OI5V was prepared from o-trimethylstannyl-cyclopentanevesamicol (OT5V) by the iododestannylation reaction under no-carrier-added conditions. In vivo biodistribution study of [125I]OI5V in blood, brain regions and major organs of rats was performed at 2, 10, 30 and 60 min post-injection. In vivo blocking study and ex vivo autoradiography were performed to assess the binding selectivity of [125I]OI5V for σ-1 receptor. SPECT-CT imaging study was performed using [123I]OI5V. RESULTS OI5V demonstrated high selective binding affinity for σ-1R in vitro. In the biodistribution study, the blood-brain barrier (BBB) permeability of [125I]OI5V was high and the accumulation of [125I]OI5V in the rat cortex at 2 min post-injection exceeded 2.00%ID/g. In the in vivo blocking study, the accumulation of [125I]OI5V in the brain was significantly blocked by co-administration of 0.5 μmol of SA4503 and 1.0 μmol of pentazocine. Ex vivo autoradiography revealed that the regional brain accumulation of [125I]OI5V was similar to σ-1R-rich regions of the rat brain. SPECT images of [123I]OI5V in the rat brain reflected the distribution of sigma receptors in the brain. CONCLUSIONS This study confirmed that [125/123I]OI5V selectively binds σ-1R in the rat brain in vivo. [123I]OI5V was suggested to be useful as a σ-1R ligand for SPECT.
Collapse
Affiliation(s)
- Taiki Shigeno
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa, Ishikawa, Japan
| | - Takashi Kozaka
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa, Ishikawa, Japan
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa , Ishikawa, Japan
| | - Yoji Kitamura
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa, Ishikawa, Japan
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa , Ishikawa, Japan
| | - Kazuma Ogawa
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa , Ishikawa, Japan
| | - Junichi Taki
- Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan
| | - Seigo Kinuya
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa, Ishikawa, Japan
- Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan
| | - Kazuhiro Shiba
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa, Ishikawa, Japan.
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa , Ishikawa, Japan.
| |
Collapse
|
2
|
Miwa D, Kitamura Y, Kozaka T, Shigeno T, Ogawa K, Taki J, Kinuya S, Shiba K. (-)-o-[ 11 C]methyl-trans-decalinvesamicol ((-)-[ 11 C]OMDV) as a PET ligand for the vesicular acetylcholine transporter. Synapse 2020; 74:e22176. [PMID: 32500935 DOI: 10.1002/syn.22176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 05/28/2020] [Accepted: 05/28/2020] [Indexed: 11/10/2022]
Abstract
To develop a PET imaging agent to visualize brain cholinergic neurons and synaptic changes caused by Alzheimer's disease, (-)- and (+)-o-[11 C]methyl-trans-decalinvesamicol ([11 C]OMDV) were isolated and investigated for differences in not only their binding affinity and selectivity to vesicular acetylcholine transporter (VAChT), but also their in vivo activities. [11 C]OMDV has a high binding affinity for VAChT both in vitro and in vivo. Racemic OMDV and o-trimethylstannyl-trans-decalinvesamicol (OTDV), which are precursors for synthesis of [11 C]OMDV, were separated into (-)-optical isomers ((-)-OMDV and (-)-OTDV) and (+)-optical isomers ((+)-OMDV and (+)-OTDV) by HPLC. In the in vitro binding assay, (-)-OMDV(7.2 nM) showed eight times higher binding affinity (Ki) to VAChT than that of (+)-OMDV(57.5 nM). In the biodistribution study, the blood-brain barrier permeability of both enantiomers ((-)-[11 C]OMDV and (+)-[11 C]OMDV) was similarly high (about 1.0%ID/g) at 2 min post-injection. However, (+)-[11 C]OMDV clearance from the brain was faster than (-)-[11 C]OMDV. In the in vivo blocking study, accumulation of (-)-[11 C]OMDV in the cortex was markedly decreased (approximately 30% of control) by coadministration of vesamicol, and brain uptake of (-)-[11 C]OMDV was not significantly altered by coadministration of (+)-pentazocine or (+)-3-(3-hydroxyphenyl)-N-propylpiperidine ((+)-3-PPP). PET-CT imaging revealed inhibition of the rat brain uptake of (-)-[11 C]OMDV by coadministration of vesamicol. In conclusion, (-)-[11 C]OMDV, which is an enantiomer of OMDV, selectively binds to VAChT with high affinity in the rat brain in vivo. (-)-[11 C]OMDV may be utilized as a potential PET ligand for studying presynaptic cholinergic neurons in the brain.
Collapse
Affiliation(s)
- Daisuke Miwa
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan
| | - Yoji Kitamura
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan
| | - Takashi Kozaka
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan
| | - Taiki Shigeno
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan
| | - Kazuma Ogawa
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Junichi Taki
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Seigo Kinuya
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
| | - Kazuhiro Shiba
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa, Japan
| |
Collapse
|
3
|
In Vivo and In Vitro Characteristics of Radiolabeled Vesamicol Analogs as the Vesicular Acetylcholine Transporter Imaging Agents. CONTRAST MEDIA & MOLECULAR IMAGING 2018; 2018:4535476. [PMID: 30008624 PMCID: PMC6020543 DOI: 10.1155/2018/4535476] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/27/2017] [Revised: 04/03/2018] [Accepted: 05/02/2018] [Indexed: 12/29/2022]
Abstract
The vesicular acetylcholine transporter (VAChT), a presynaptic cholinergic neuron marker, is a potential internal molecular target for the development of an imaging agent for early diagnosis of neurodegenerative disorders with cognitive decline such as Alzheimer's disease (AD). Since vesamicol has been reported to bind to VAChT with high affinity, many vesamicol analogs have been studied as VAChT imaging agents for the diagnosis of cholinergic neurodeficit disorder. However, because many vesamicol analogs, as well as vesamicol, bound to sigma receptors (σ1 and σ2) besides VAChT, almost all the vesamicol analogs have been shown to be unsuitable for clinical trials. In this report, the relationships between the chemical structure and the biological characteristics of these developed vesamicol analogs were investigated, especially the in vitro binding profile and the in vivo regional brain accumulation.
Collapse
|
4
|
Uno I, Kozaka T, Miwa D, Kitamura Y, Azim MAU, Ogawa K, Taki J, Kinuya S, Shiba K. In Vivo Differences between Two Optical Isomers of Radioiodinated o-iodo-trans-decalinvesamicol for Use as a Radioligand for the Vesicular Acetylcholine Transporter. PLoS One 2016; 11:e0146719. [PMID: 26752172 PMCID: PMC4713475 DOI: 10.1371/journal.pone.0146719] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 12/20/2015] [Indexed: 01/03/2023] Open
Abstract
PURPOSE To develop a superior VAChT imaging probe for SPECT, radiolabeled (-)-OIDV and (+)-OIDV were isolated and investigated for differences in their binding affinity and selectivity to VAChT, as well as their in vivo activities. PROCEDURES Radioiodinated o-iodo-trans-decalinvesamicol ([125I]OIDV) has a high binding affinity for vesicular acetylcholine transporter (VAChT) both in vitro and in vivo. Racemic [125I]OIDV was separated into its two optical isomers (-)-[125I]OIDV and (+)-[125I]OIDV by HPLC. To investigate VAChT binding affinity (Ki) of two OIDV isomers, in vitro binding assays were performed. In vivo biodistribution study of each [125I]OIDV isomer in blood, brain regions and major organs of rats was performed at 2,30 and 60 min post-injection. In vivo blocking study were performed to reveal the binding selectivity of two [125I]OIDV isomers to VAChT in vivo. Ex vivo autoradiography were performed to reveal the regional brain distribution of two [125I]OIDV isomers and (-)-[123I]OIDV for SPECT at 60 min postinjection. RESULTS VAChT binding affinity (Ki) of (-)-[125I]OIDV and (+)-[125I]OIDV was 22.1 nM and 79.0 nM, respectively. At 2 min post-injection, accumulation of (-)-[125I]OIDV was the same as that of (+)-[125I]OIDV. However, (+)-[125I]OIDV clearance from the brain was faster than (-)-[125I]OIDV. At 30 min post-injection, accumulation of (-)-[125I]OIDV (0.62 ± 0.10%ID/g) was higher than (+)-[125I]OIDV (0.46 ± 0.07%ID/g) in the cortex. Inhibition of OIDV binding showed that (-)-[125I]OIDV was selectively accumulated in regions known to express VAChT in the rat brain, and ex vivo autoradiography further confirmed these results showing similar accumulation of (-)-[125I]OIDV in these regions. Furthermore, (-)-[123I]OIDV for SPECT showed the same regional brain distribution as (-)-[125I]OIDV. CONCLUSION These results suggest that radioiodinated (-)-OIDV may be a potentially useful tool for studying presynaptic cholinergic neurons in the brain.
Collapse
Affiliation(s)
- Izumi Uno
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Ishikawa, 920-8640, Japan.,Clinical Laboratory, Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8640, Japan
| | - Takashi Kozaka
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Ishikawa, 920-8640, Japan
| | - Daisuke Miwa
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Ishikawa, 920-8640, Japan.,Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, 920-8640, Japan
| | - Yoji Kitamura
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Ishikawa, 920-8640, Japan
| | - Mohammad Anwar-Ul Azim
- National Institute of Nuclear Medicine and Allied Sciences; Bangladesh Atomic Energy Commission, BSM Medical University Campus, Dhaka-1000, Bangladesh
| | - Kazuma Ogawa
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, 920-8640, Japan
| | - Junichi Taki
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, 920-8640, Japan
| | - Seigo Kinuya
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, 920-8640, Japan
| | - Kazuhiro Shiba
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Ishikawa, 920-8640, Japan
| |
Collapse
|
5
|
Kitamura Y, Kozaka T, Miwa D, Uno I, Azim MAU, Ogawa K, Taki J, Kinuya S, Shiba K. Synthesis and evaluation of a new vesamicol analog o-[(11)C]methyl-trans-decalinvesamicol as a PET ligand for the vesicular acetylcholine transporter. Ann Nucl Med 2015; 30:122-9. [PMID: 26608176 DOI: 10.1007/s12149-015-1039-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 11/08/2015] [Indexed: 11/26/2022]
Abstract
INTRODUCTION We focused on the vesicle acetyl choline transporter (VAChT) as target for early diagnosis of Alzheimer's diseases because the dysfunction of the cholinergic nervous system is closely associated with the symptoms of AD, such as problem in recognition, memory, and learning. Due to its low binding affinity for the sigma receptors (σ-1 and σ-2), o-methyl-trans-decalinvesamicol (OMDV) demonstrated a high binding affinity and selectivity for vesicular acetyl choline transporter (VAChT). [(11)C]OMDV was prepared and investigated the potential as a new PET ligand for VAChT imaging through in vivo evaluation. METHOD [(11)C]OMDV was prepared by a palladium-promoted cross-coupling reaction using [(11)C]methyl iodide, with a radiochemical yield of 60-75%, a radiochemical purity of greater than 98%, and a specific activity of 5-10 TBq/mmol 30 min after EOB. In vivo biodistribution study of [(11)C]OMDV in blood, brain regions and major organs of rats was performed at 2, 10, 30 and 60 min post-injection. In vivo blocking study and PET-CT imaging study were performed to check the binding selectivity of [(11)C]OMDV for VAChT. RESULTS In vivo studies demonstrated [(11)C]OMDV passage through the blood-brain barrier (BBB) and accumulation in the rat brain. The regional brain accumulation of [(11)C]OMDV was significantly inhibited by co-administration of vesamicol. In contrast, brain accumulation of [(11)C]OMDV was not significantly altered by co-administration of (+)-pentazocine, a selective σ-1 receptor ligand, or (+)-3-(3-hydroxyphenyl)-N-propylpiperidine [(+)-3-PPP], a σ-1 and σ-2 receptor ligand. PET-CT imaging revealed inhibition of [(11)C]OMDV accumulation in the brain by co-administration of vesamicol. CONCLUSION [(11)C]OMDV selectively binds to VAChT with high affinity in the rat brain in vivo, and that [(11)C]OMDV may be utilized in the future as a specific VAChT ligand for PET imaging.
Collapse
Affiliation(s)
- Yoji Kitamura
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan.
| | - Takashi Kozaka
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan.
| | - Daisuke Miwa
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan
| | - Izumi Uno
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan
| | - Mohammad Anwar-Ul Azim
- National Institute of Nuclear Medicine and Allied Sciences, Bangladesh Atomic Energy Commission, BSM Medical University Campus, Block-D, 7th-10th floor, Shahbagh, Dhaka, 1000, Bangladesh
| | - Kazuma Ogawa
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan
| | - Junichi Taki
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan
| | - Seigo Kinuya
- Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan
| | - Kazuhiro Shiba
- Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8640, Japan.
| |
Collapse
|
6
|
Azim MAU, Kozaka T, Uno I, Miwa D, Kitamura Y, Ogawa K, Makino A, Kiyono Y, Shiba K. The potential ofo-bromo-trans-decalinvesamicol as a new PET ligand for vesicular acetylcholine transporter imaging. Synapse 2014; 68:445-53. [DOI: 10.1002/syn.21756] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2014] [Revised: 05/28/2014] [Accepted: 06/14/2014] [Indexed: 12/31/2022]
Affiliation(s)
- Mohammad Anwar-ul Azim
- Division of Tracer Kinetics; Advanced Science Research Center, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
- Graduate School of Natural Science and Technology; Kanazawa University; Kakuma 920-1192 Japan
| | - Takashi Kozaka
- Division of Tracer Kinetics; Advanced Science Research Center, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
- College of Medical; Pharmaceutical and Health Sciences, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
| | - Izumi Uno
- Division of Tracer Kinetics; Advanced Science Research Center, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
- College of Medical; Pharmaceutical and Health Sciences, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
| | - Daisuke Miwa
- Division of Tracer Kinetics; Advanced Science Research Center, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
- College of Medical; Pharmaceutical and Health Sciences, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
| | - Yoji Kitamura
- Division of Tracer Kinetics; Advanced Science Research Center, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
- Graduate School of Natural Science and Technology; Kanazawa University; Kakuma 920-1192 Japan
- College of Medical; Pharmaceutical and Health Sciences, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
| | - Kazuma Ogawa
- College of Medical; Pharmaceutical and Health Sciences, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
| | - Akira Makino
- Biomedical Imaging Research Center; University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun; Fukui Prefecture 910-1193 Japan
| | - Yasushi Kiyono
- Biomedical Imaging Research Center; University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun; Fukui Prefecture 910-1193 Japan
| | - Kazuhiro Shiba
- Division of Tracer Kinetics; Advanced Science Research Center, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
- Graduate School of Natural Science and Technology; Kanazawa University; Kakuma 920-1192 Japan
- College of Medical; Pharmaceutical and Health Sciences, Kanazawa University; 13-1 Takara-machi Kanazawa Ishikawa 920-8640 Japan
| |
Collapse
|